Halozyme Therapeutics has proposed an unsolicited takeover bid for German drug developer Evotec, offering €11 per share in an all-cash transaction. This bid values Evotec at approximately €2 billion ($2.1 billion), representing a 27% premium over Evotec’s last closing price. Following the announcement, Evotec's shares surged by 20%. The potential acquisition is seen as a strategic move for Halozyme to enhance its drug discovery and development portfolio. Additionally, Triton Partners recently acquired a 10% stake in Evotec, which may indicate competitive interest in the company. Meanwhile, BeiGene has announced plans to change its name to BeOne Medicines as part of its rebranding efforts to support growth in the U.S. and European markets.